Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Prim

BATS-CHIXE:PRME
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRME
BATS-CHIXE
€204M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Prim, S.A., through its subsidiaries, designs, manufactures, commercializes, installs, and maintains hospital and orthopaedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, and geriatrics, as well as daily living aids in Spain and internationally. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
PRME Share Price and Events
7 Day Returns
0%
BATS-CHIXE:PRME
-2.2%
GB Medical Equipment
-0.8%
GB Market
1 Year Returns
-
BATS-CHIXE:PRME
16.3%
GB Medical Equipment
8.5%
GB Market
PRME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prim (PRME) 0% 0% - - 31.6% -
GB Medical Equipment -2.2% 2% -7.5% 16.3% 22.8% 58.4%
GB Market -0.8% -0.3% 2.1% 8.5% 4% 9.5%
1 Year Return vs Industry and Market
  • No trading data on PRME.
  • No trading data on PRME.
Price Volatility
PRME
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Prim's competitors could be found in our database.

Value

 Is Prim undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Prim to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Prim.

BATS-CHIXE:PRME Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in EUR € .577900
Payout Ratio Company Filings (2019-09-30) 5999.2%
Discount Rate (Cost of Equity) See below 7.4%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:PRME
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 7.5%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.844 (1 + (1- 25%) (4.71%))
0.927
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.927 * 7.46%)
7.44%

Discounted Cash Flow Calculation for BATS-CHIXE:PRME using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Prim is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

BATS-CHIXE:PRME Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= €0.58 / (7.44% - 0.53%)
€7.58
BATS-CHIXE:PRME Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:PRME represents 0.95196x of BME:PRM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.95196x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 8.36 x 0.95196
€7.96
Value per share (EUR) From above. €7.96
Current discount Discount to share price of €10.90
= -1 x (€10.90 - €7.96) / €7.96
-37%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Prim is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prim's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prim's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:PRME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €0.70
BME:PRM Share Price ** BME (2019-09-11) in EUR €11.45
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 30.63x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 752 Publicly-Listed Companies 17.27x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prim.

BATS-CHIXE:PRME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:PRM Share Price ÷ EPS (both in EUR)

= 11.45 ÷ 0.70

16.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prim is good value based on earnings compared to the GB Medical Equipment industry average.
  • Prim is good value based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Prim's expected growth come at a high price?
Raw Data
BATS-CHIXE:PRME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 1.68x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 562 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prim, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prim's assets?
Raw Data
BATS-CHIXE:PRME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €6.24
BME:PRM Share Price * BME (2019-09-11) in EUR €11.45
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 19 Publicly-Listed Medical Equipment Companies 3.11x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,311 Publicly-Listed Companies 1.52x
BATS-CHIXE:PRME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:PRM Share Price ÷ Book Value per Share (both in EUR)

= 11.45 ÷ 6.24

1.84x

* Primary Listing of Prim.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prim is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Prim's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Prim has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Prim expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prim has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.7%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prim expected to grow at an attractive rate?
  • Unable to compare Prim's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Prim's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Prim's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:PRME Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.7%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.8%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 12.4%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:PRME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:PRME Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 146 12
2019-06-30 142 -4 13
2019-03-31 137 14
2018-12-31 134 7 14
2018-09-30 132 14
2018-06-30 128 10 14
2018-03-31 124 15
2017-12-31 121 11 14
2017-09-30 117 14
2017-06-30 116 8 14
2017-03-31 114 13
2016-12-31 110 10 13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Prim is high growth as no earnings estimate data is available.
  • Unable to determine if Prim is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:PRME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Prim Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:PRME Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 0.70
2019-06-30 0.72
2019-03-31 0.81
2018-12-31 0.81
2018-09-30 0.81
2018-06-30 0.82
2018-03-31 0.83
2017-12-31 0.80
2017-09-30 0.82
2017-06-30 0.83
2017-03-31 0.79
2016-12-31 0.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prim will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Prim is trading at Prim'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Prim's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Prim's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prim has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Prim performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prim's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prim's year on year earnings growth rate has been positive over the past 5 years.
  • Prim's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Prim's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Prim's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prim Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:PRME Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 146.04 12.19 54.57
2019-06-30 141.69 12.66 53.64
2019-03-31 136.61 13.81 53.15
2018-12-31 134.43 14.12 52.05
2018-09-30 132.12 14.19 48.70
2018-06-30 128.01 14.14 47.97
2018-03-31 123.86 14.53 47.92
2017-12-31 121.27 13.90 46.83
2017-09-30 116.89 13.87 46.61
2017-06-30 115.78 14.05 45.59
2017-03-31 114.29 13.34 45.14
2016-12-31 110.10 13.10 44.17
2016-09-30 107.03 11.36 41.31
2016-06-30 105.87 11.13 41.09
2016-03-31 101.78 10.86 40.18
2015-12-31 99.23 10.70 40.11
2015-09-30 99.32 11.06 39.37
2015-06-30 96.84 10.66 38.96
2015-03-31 95.10 10.13 26.57
2014-12-31 94.21 9.96 39.61
2014-09-30 90.33 8.81 38.44
2014-06-30 88.95 9.27 38.08
2014-03-31 88.37 9.71 37.83
2013-12-31 87.00 8.29 37.28
2013-09-30 87.44 8.10 37.49
2013-06-30 84.09 7.21 36.76
2013-03-31 86.42 7.45 37.41
2012-12-31 85.82 8.77 36.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Prim has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Prim used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Prim has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Prim's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prim has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Prim's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prim's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prim is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prim's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Prim's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 11.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prim Company Filings, last reported 2 months ago.

BATS-CHIXE:PRME Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 108.19 9.58 10.28
2019-06-30 106.95 8.73 19.39
2019-03-31 112.47 3.19 18.25
2018-12-31 108.84 0.76 16.87
2018-09-30 106.24 2.78 19.28
2018-06-30 104.37 1.95 29.02
2018-03-31 109.07 2.21 27.70
2017-12-31 106.07 2.14 24.03
2017-09-30 102.10 1.21 24.40
2017-06-30 100.72 1.95 28.71
2017-03-31 103.18 1.15 24.39
2016-12-31 100.84 1.64 21.38
2016-09-30 94.22 1.33 16.55
2016-06-30 91.69 1.95 26.06
2016-03-31 94.18 1.43 16.59
2015-12-31 92.25 2.17 18.94
2015-09-30 89.63 2.87 13.07
2015-06-30 88.85 2.80 24.19
2015-03-31 94.96 2.71 16.06
2014-12-31 92.66 2.78 13.69
2014-09-30 89.61 3.35 12.55
2014-06-30 87.23 3.00 16.44
2014-03-31 86.30 5.70 21.91
2013-12-31 83.80 5.59 2.98
2013-09-30 82.20 3.74 6.10
2013-06-30 80.60 6.32 13.09
2013-03-31 80.13 6.76 23.85
2012-12-31 78.20 7.83 19.70
  • Prim's level of debt (8.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.7% vs 8.9% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Prim earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Prim's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prim has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Prim's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
5.05%
Current annual income from Prim dividends.
If you bought €2,000 of Prim shares you are expected to receive €101 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Prim's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (1.96%).
  • Prim's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.25%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:PRME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 1.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 679 Stocks 4.5%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:PRME Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-04-30 0.578 5.159
2018-04-20 0.578 4.817
2018-02-28 0.578 5.182
2017-04-26 0.460 4.395
2017-02-28 0.460 4.881
2016-05-03 0.375 4.352
2015-05-29 0.531 5.867
2014-08-01 0.202 3.037
2014-05-02 0.202 3.269
2013-11-19 0.193 3.357
2013-08-30 0.193 3.469
2013-04-30 0.193 3.534
2013-02-28 0.190 3.713
2012-08-31 0.190 3.990
2012-02-29 0.190 5.325
2011-08-31 0.190 4.818
2010-06-21 0.190 3.422
2009-12-29 0.082 1.186
2009-03-02 0.176 2.635
2009-02-27 0.252 3.675

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Prim's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.5x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Prim's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prim afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prim has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Prim's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Prim has no CEO, or we have no data on them.
Management Team

Victoriano Prim Gonzalez

TITLE
Chairman & MD
COMPENSATION
€282K

Jose Luis Meijide Garcia

TITLE
Vice Secretary and Director
COMPENSATION
€50K

Ignacio Arraez Bertolín

TITLE
Vice-Secretary & Director
COMPENSATION
€50K

Pedro Prim

TITLE
Board of Directors

Victoriano Prim Gonzalez

TITLE
Chairman & MD
COMPENSATION
€282K

Andres Estaire Alvarez

TITLE
Vice Chairman
COMPENSATION
€50K

Jose Luis Meijide Garcia

TITLE
Vice Secretary and Director
COMPENSATION
€50K
TENURE
12.5 yrs

Ignacio Arraez Bertolín

TITLE
Vice-Secretary & Director
COMPENSATION
€50K

Enrique Gimenez-Reyna Rodríguez

TITLE
Independent Director
COMPENSATION
€50K

Maria Belen Amatriain Corbi

TITLE
Independent Director
COMPENSATION
€4K

Jorge Prim Martinez

TITLE
Proprietary Director
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Prim individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Nov 19 Buy José Ignacio Comenge Sánchez-Real Individual 14. Nov 19 14. Nov 19 1,016,779 €11.00 €11,184,569
X
Management checks
We assess Prim's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prim has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Prim, S.A., through its subsidiaries, designs, manufactures, commercializes, installs, and maintains hospital and orthopaedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, and geriatrics, as well as daily living aids in Spain and internationally. The company offers products for plastic, endo, E.N.T., and neuro surgeries; pain units; cardiovascular products; products for traumatology; and biomaterials. It also provides orthopedic products, such as ankle and knee supports, girdles, wristbands, hyperextension braces, prostheses and prosthetic components, incontinence and electro medical products, etc. through orthopedic supply shops, pharmacies, and cooperatives; and customized technical orthopedic products for people with disabilities. In addition, the company manufactures podiatry and orthotics products, as well as distributes technical aids, health care articles, and OTC products. Further, it engages in management of wellness projects, including spas, hotels, resorts, home, sports centers, and thalassotherapy facilities. Prim, S.A. was founded in 1870 and is based in Móstoles, Spain.

Details
Name: Prim, S.A.
PRME
Exchange: BATS-CHIXE
Founded: 1870
€203,585,517
17,326,427
Website: http://www.prim.es
Address: Prim, S.A.
Polígono Industrial número 1,
Calle Yolanda González, número 15,
Móstoles,
Madrid, 28938,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME PRM Bearer Shares Bolsas y Mercados Espanoles ES EUR 02. Jan 1992
DB 5P1 Bearer Shares Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0FP0 Bearer Shares London Stock Exchange GB EUR 02. Jan 1992
BATS-CHIXE PRME Bearer Shares BATS 'Chi-X Europe' GB EUR 02. Jan 1992
Number of employees
Current staff
Staff numbers
588
Prim employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/09 19:34
End of day share price update: 2019/09/11 00:00
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.